Nitroglycerin in Non-small Cell Lung Cancer (Nitroglycerin)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01210378|
Recruitment Status : Terminated (Accrual stopped)
First Posted : September 28, 2010
Last Update Posted : February 15, 2019
Nitroglycerin is a nitric oxide donor which is mainly known as a vasodilating agent used in ischemic heart disease. It has also been shown to increase tumor blood flow in animal and human tumors.
The addition of nitroglycerin to chemotherapy in non small cell lung cancer has been shown to generate very favorable response rates with respect to standard treatment schedules. Theoretically nitroglycerin might reduce resistance to chemotherapy via a plethora of different effects: better tumor perfusion, direct effects of NO on cancer cells, increase in activated p53 protein and via an increased blood flow in the tumour with as consequence a higher drug concentration in the tumor  .
In mice, nitric oxide donors such as isosorbide dinitrate have been shown to decrease tumor hypoxia by better tumor perfusion, which could enhance radiotherapy responses .
To date these combined effects have not been tested in humans. In this trial we would like to demonstrate the effect of nitroglycerin on tumor perfusion and hypoxia in non small cell lung cancer (using DCE and HX4 scanning), providing a rationale for further study and to test the effect of combining nitroglycerine to standard treatment of NSCLC (radiotherapy/chemotherapy).
|Condition or disease||Intervention/treatment||Phase|
|Non Small Cell Lung Cancer (NSCLC)||Drug: Nitroglycerin patch||Phase 2|
Namely, the failure of many different tumor types to show a lasting response chemotherapy or radiotherapy might be attributable to a lack of oxygen supply (called "hypoxia" from hereon) in a large part of the cancer cells.
Tumor hypoxia is a well-known factor negatively influencing outcome in many solid tumors, including lung cancer, head and neck cancer, etc. Hypoxic cells are more radio-resistant, more chemo-resistant and more prone to develop distant metastases than normoxic cells.
Nitroglycerin, due to it`s vasoactive effects, tends to redistribute the blood supply to the tumor, increasing tumor blood flow, hereby theoretically decreasing hypoxia.
It has been shown that NO donating drugs can alter tumor blood flow and oxygenation status in animal models . In a randomized phase 2 trial by Yasuda nitroglycerin has been successfully combined at a dose of 25 mg daily for 5 days each chemo cycle with cisplatin and vinorelbine in non small cell lung cancer, enhancing chemotherapy response, possibly due to better delivery of the anti-cancer drugs in the tumor. The toxicity profile between the 2 arms was not significantly different.
The effects of nitroglycerin or other donating drugs on cancer have been found to be numerous: not only is there an increase in tumor bloodflow, also direct effects on stabilization of p53 and degradation of Hif-1 alpha have been found. Decreased hypoxic biomarkers (eg VEGF, P-glycoprotein) have been found in patients with NSCLC treated with nitroglycerin patches for 3 days prior to surgery when compared to non-treated individuals . There might also be a supplementary effect on the MHC-molecules, rendering tumor cells more "visible" to the immune system .
Furthermore, hypoxia has been shown in vitro to increase the invasiveness of cancer cells in an NO-mediated manner, which can be blocked by NO-donors. An interesting study in this respect is a non-randomized phase 2 trial by Siemens et al, in which a very low dose of nitroglycerin (Minitran 5 patch (18 mg) cut in 6 pieces, delivering 0.033 mg/h in stead of 0.2 mg/h normally) was given to patients with biochemical recurrence (PSA-failure) after primary therapy. After 24 months the PSA doubling time was more than 31 months versus 12.8 months before the start of therapy, demonstrating the inhibitory effect of nitroglycerin on prostate cancer cells. 
Due to these effects and the effect on tumor bloodflow and decrease of hypoxia nitroglycerin might also be interesting as a radiosensitizing agent.
Currently a Mexican phase 2 trial is recruiting 40 patients to evaluate the efficacy of nitroglycerin added to concurrent chemoradiotherapy in NSCLC stage III. (Clinical trials.gov identifier NCT00886405).
The aim of the present study is not only to demonstrate the effect of nitroglycerin on perfusion and hypoxia through (HX4-)scanning of patients, but also documenting the efficacy of the approach of giving nitroglycerin in an on/off (12h/12h) schedule to people receiving (chemo-)/radiotherapy, whilst monitoring toxicity.
The on-off schedule is chosen because of the existence of a tolerance effect on the vascular system, hence diminishing the effect of nitroglycerin already after the first 24 hours.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||47 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Nitroglycerin as a Sensitizer in the Treatment of Non Small Cell Lung Cancer: a Phase II Trial|
|Actual Study Start Date :||December 2011|
|Actual Primary Completion Date :||September 2016|
|Actual Study Completion Date :||March 2017|
Drug: Nitroglycerin patch
- Increase of 2 year overall survival of 15% vs historical controls [ Time Frame: 2 years ]
- Demonstrate effect on enhancement on tumor perfusion [ Time Frame: 3 days ]
- Toxicity [ Time Frame: 7 weeks ]
- Demonstrate the effect on enhancement of tumor oxygenation [ Time Frame: 3 days ]
- Evaluating the possible value of Perfusion CT and hypoxia scans on treatment with nitroglycerin of NSCLC [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01210378
|Maastricht, Netherlands, 6229 ET|
|Principal Investigator:||Philippe Lambin, MD, PhD||Maastro Clinic, The Netherlands|